Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esketamine - Johnson & Johnson

Drug Profile

Esketamine - Johnson & Johnson

Alternative Names: Esketamine nasal spray; JNJ-54135419; JNJ-54135419-AAA; JNJ-5419; S-ketamine; SPRAVATO

Latest Information Update: 15 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder

Most Recent Events

  • 09 Mar 2021 Registered for Major depressive disorder (Treatment-resistant) in Australia (Intranasal)
  • 08 Feb 2021 Registered for Major depressive disorder (Adjunctive treatment) in Liechtenstein, Norway, Iceland, Iceland, European Union (Intranasal)
  • 11 Dec 2020 The Committee for Medicinal Products for Human Use (CHMP) adoptes a positive opinion, recommending expanded use of esketamine for Major depressive disorder (Adjunctive treatment)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top